Perrigo Company plc reports recurring developments as a pure-play consumer health company focused on over-the-counter self-care products, store-brand private label offerings, and branded health and wellness products primarily in North America and Europe. Company updates cover operating results from continuing operations, category performance, dividends, investor presentations, and portfolio actions under its Three-S plan to stabilize, streamline, and strengthen the business.
News also addresses Perrigo's product-category reporting and brand momentum across Self Care and Specialty Care, including names such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®. Recent corporate developments include the completed divestiture of the Dermacosmetics business and the use of portfolio proceeds for balance-sheet debt reduction.
Perrigo (NYSE: PRGO) announced a quarterly dividend of $0.290 per share, payable on December 16, 2025 to shareholders of record on November 28, 2025. The declaration signals a scheduled cash distribution to shareholders and provides exact record and payment dates for investors.
For more information on Perrigo's business and financial disclosures, investors are directed to the company's SEC filings and investor relations resources.
Perrigo (NYSE: PRGO) announced it will release third quarter 2025 financial results on Wednesday, November 5, 2025 and host a conference call at 8:30 A.M. EST.
The call will stream live via webcast in the investor relations section at perrigo.investorroom.com/events-webcasts and is accessible by phone (US: 800-836-8184; International: 646-357-8785) with reference ID 03742. A taped replay will be available beginning ~12:00 P.M. EST on November 5 through midnight on November 12, 2025 (replay dial 888-660-6345 or International 646-517-4150; access code 03742#).
Company background: Perrigo is a self-care products company with leading store-brand and branded portfolios including Opill, Mederma, Compeed, EllaOne, and Jungle Formula.
Perrigo (NYSE: PRGO) announced on October 9, 2025 a brand collaboration between Opill and Chillhouse called "Opill and Chill". The partnership launches three limited-edition press-on nail sets — Same Time Tomorrow, OTC Chill and In Control — with online and retail availability.
For every Opill-themed Chill Tips set sold, Perrigo will donate one pack of Opill to NY Birth Control Access Project for statewide distribution. The collaboration includes an in-person activation at Chillhouse Soho in NYC on Oct. 9, 2025 from 1–5 PM ET, with free applications for the first 200 guests and live conversations on reproductive health.
Products are available at Chillhouse.com and Amazon while supplies last.
Perrigo (NYSE:PRGO), a leading self-care company, announced that its President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will participate in one-on-one investor meetings at the Barclays Global Consumer Staples Conference on September 3rd, 2025.
The company, with over a century of experience, specializes in over-the-counter (OTC) self-care products in North America and Europe. Their business model combines store brand private label offerings with branded products including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.
Perrigo (NYSE:PRGO) reported Q2 2025 financial results with net sales of $1.06 billion, down 0.9% year-over-year. The company's adjusted EPS reached $0.57, up 7.5% from the previous year, despite challenging market conditions. The company is executing its 'Three-S' strategic plan (Stabilize, Streamline, and Strengthen) and recently announced the sale of its Dermacosmetics business.
Key financial metrics include adjusted operating income of $135 million (down 2.9%) and an adjusted operating margin of 12.8% (down 30 basis points). The company maintained its full-year 2025 adjusted EPS target range of $2.90 - $3.10, although net sales growth is expected to be at the lower end of guidance due to infant formula industry dynamics and market consumption trends.
Project Energize, launched in Q1 2024, has achieved gross annual savings of $159 million with reinvestment of $27 million, targeting total annualized pre-tax savings of $140-170 million by the end of 2026.
Perrigo (NYSE: PRGO), a leading global self-care company, has declared a quarterly dividend of $0.290 per share. The dividend will be payable on September 16, 2025, to shareholders of record on August 29, 2025.
The company, with over a century of experience, specializes in over-the-counter (OTC) self-care products in North America and Europe. Perrigo's business model combines store brand private label offerings with leading brands including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.
[ "Consistent dividend payment demonstrates financial stability", "Strong market presence with century-long experience in self-care products", "Diversified portfolio combining private label and branded products" ]Perrigo (NYSE: PRGO), a leading provider of Consumer Self-Care Products, announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12th at 9:00 AM EDT.
The company, a pioneer in the over-the-counter (OTC) self-care market, has over a century of experience providing health and wellness solutions in North America and Europe. Perrigo's business model combines store brand private label offerings with leading brands including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.
Perrigo (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has scheduled the release of its second quarter 2025 financial results for Wednesday, August 6th, 2025. The company will host a conference call at 8:30 A.M. (EST) to discuss the results.
Perrigo is a pure-play self-care company specializing in over-the-counter (OTC) health and wellness solutions in North America and Europe. Their business model combines store brand private label offerings with leading brands including Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®.
Perrigo (NYSE: PRGO) has announced an agreement to sell its Dermacosmetics branded business to KKR-managed Kairos Bidco AB for up to €327 million. The deal includes €300 million in upfront cash and up to €27 million in potential milestone payments tied to net sales performance over three years.
The transaction, expected to close in Q1 2026, is part of Perrigo's 'Three-S' strategic plan to Stabilize, Streamline, and Strengthen the organization. The divested brands include ACO, Biodermal, Emolium, and Iwostin, which generated approximately €125 million in net sales and about 5% of Perrigo's 2024 adjusted operating income.
Proceeds will be directed towards previously announced capital allocation priorities, including strengthening the company's balance sheet. The deal remains subject to regulatory approvals and works council consultation.
Perrigo (NYSE: PRGO), a leading provider of Consumer Self-Care Products, has announced a strategic organizational restructuring to optimize its global Category-Led, Market Activation Growth Model. The company is making key leadership changes, with Roberto Khoury appointed as EVP & Chief Commercial Officer to lead global market activation, while Triona Schmelter, EVP & President of Consumer Self-Care Americas (CSCA), will depart the organization.
The reorganization aims to enhance agility, accelerate innovation, and drive sustainable growth as part of Perrigo's multi-year Stabilize, Streamline and Strengthen ('Three-S') plan. The company will centralize its global brand-building capabilities while maintaining market-empowered activation and commercial excellence. The restructuring will not impact Perrigo's full-year 2025 adjusted EPS guidance or reporting segments.
The implementation will occur over the coming months, following all required legal consultation processes. The roles of EVP and President CSCI and EVP and President CSCA will be discontinued as part of this organizational alignment.